Triptolide Conjugates for Enhanced Solubility and Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Triptolide, a bioactive compound, faces limitations in preclinical development and clinical applications due to poor water solubility, narrow therapeutic index, and short half-life in vivo, despite efforts to improve its aqueous solubility and therapeutic targeting through various conjugates.
Innovation Solution
Development of triptolide conjugates with enhanced aqueous solubility, therapeutic index, and longer half-life, including specific chemical structures and pharmaceutical compositions, for treating cancer and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If triptolide is used directly, then therapeutic efficacy is achieved, but water solubility is poor
Solution Approach 1:
The patent employs prodrug strategies where triptolide is conjugated with water-soluble carriers (such as polyethylene glycol, amino acids, or carboxylic acid moieties) to create an intermediary compound that enhances solubility while maintaining therapeutic activity through in vivo conversion to the active triptolide form
Solution Approach 2:
The patent modifies the chemical parameters of triptolide by introducing various functional groups and molecular structures to prodrug candidates, changing its physical properties (solubility) while preserving or enhancing its biological activity through controlled release mechanisms
2Duration of action of moving object
If triptolide is used directly, then immunosuppressive and anti-inflammatory effects are achieved, but half-life time is very short
Solution Approach 1:
The patent applies preliminary action by pre-conjugating triptolide with protective and solubilizing moieties that remain attached during circulation, allowing the drug to reach target tissues before releasing the active triptolide, thereby extending half-life and improving therapeutic index
Solution Approach 2:
The patent uses carrier molecules as intermediaries that protect triptolide from rapid metabolism and clearance, extending its circulation time while maintaining therapeutic effectiveness through controlled release at target sites
3Quantity of substance
If prodrugs are developed to improve water solubility, then aqueous solubility increases, but therapeutic index is not significantly altered
Solution Approach 1:
The patent applies local quality by designing prodrugs with specific functional groups and molecular structures that provide water solubility in the circulation environment while enabling selective activation and release of active triptolide at the target disease site, thereby improving both solubility and therapeutic index simultaneously
4Quantity of substance
If prodrugs are developed to improve water solubility, then aqueous solubility increases, but half-life time is not significantly altered
Solution Approach 1:
The patent employs composite material strategies by combining triptolide with various polymer carriers, amino acid conjugates, or other molecular structures that provide both water solubility and extended circulation half-life, creating a composite prodrug system that addresses multiple limitations simultaneously
Data Source
AI summary
This disclosure provides triptolide-conjugates, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, as well methods of using such compounds in the treatment of conditions/diseases, such as those relating to cancer, immunomodulation and/or inflammation.